About
Curtis Jamison Perry, MD, PhD, is a Clinical Assistant Professor in the Department of Internal Medicine at Yale School of Medicine, specializing in Medical Oncology and Hematology. He holds a dual degree from Yale University (MD in 2018 and PhD in Immunobiology in 2018). His research focuses on cancer immunotherapy, tumor immunity, and the mechanisms of combination therapies in melanoma and other cancers. He has contributed to studies on BRAF/MEK inhibitors, PD-1/PD-L1 pathways, and myeloid cell targeting in immunotherapeutic strategies.
Education:
- MD: Yale School of Medicine, 2018
- PhD in Immunobiology: Yale University, 2018
Research Interests:
Dr. Perry investigates how immune responses can be harnessed to combat cancer, particularly through combination therapies that target oncogenic pathways and the tumor microenvironment. He explores the efficacy of immunotherapies like checkpoint inhibitors and novel agents (e.g., APX005M) in patients with metastatic melanoma and drug-resistant cancers. His work also addresses biomarkers predicting treatment outcomes and synergistic effects between immunotherapies and targeted drugs.
Publications Trends:
His articles span clinical trials, preclinical models, and translational studies in oncology. Recent work emphasizes predicting survival in melanoma patients treated with BRAF/MEK inhibitors and understanding immune cell dynamics in tumor regression. He collaborates with prominent researchers like Marcus Bosenberg and Steven Kaech, focusing on immune checkpoint inhibitors and myeloid cell modulation.
Awards:
- 2023 Young Investigator Award, American Society for Clinical Oncology
Lab & Affiliations:
His lab is affiliated with the Jeffrey Ishizuka Lab at Yale Cancer Center (300 George Street, Fl 6, New Haven, CT). He contributes to translational research bridging basic immunology and clinical oncology.
